Sulphonylurea drugs have been shown to augment glucose metabolism by both pancreatic and extrapancreatic actions. The regulation of glucose involves a modification of β-endorphin secretions via central and peripheral mechanisms. β-Endorphin participates in the regulation of feeding and is implicated both in obesity and diabetes mellitus. This study shows that glipizide could exert its pharmacological action in genetically diabetic (db/db) mice via β-endorphin secretions by a central mechanism.
GoldMSDackisCAPottashALC: Naltrexone opiate addiction and endorphins. Med Res Rev1982; 2: 211–246.
2.
MargulesDLMoissetBLewisMJ: Betaendorphin is associated with over eating in genetically obese mice (ob/ob) and rats (fa/fa). Science1978; 207: 988–991.
3.
RossierJRogerJShibasakiT: Opioid peptide and beta-melanocyte-stimulating hormone in genetically obese (ob/ob) mice during development. Proc Natl Acad Sci USA1979; 76: 2077–2080.
4.
GovoniSYangHYT: Sex differences in the content of beta-endorphin and enkephalin-like peptides in the pituitary of obese (ob/ob) mice. J Neurochem1981; 36: 1829–1833.
5.
GreenbergJEllynFPullenG: Methionine-enkephalin and β-endorphin levels in brain, pancreas, and adrenals of (db/db) mice. Endocrinology1985; 116: 328–331.
6.
WoodsSCPorteDJr: The central nervous system, pancreatic hormones, feeding and obesity. Adv Metab Disord1978; 9: 283–312.
7.
GarrisDRWilliamsSKColemanDL: Glucose utilization by the mouse brain: influence of age and diabetes. Dev Brain Res1984; 15: 141–146.
8.
GarrisDRWestRLColemanDL: Morphometric analysis of medical basal hypothalamic neuronal degeneration in diabetes (db/db) mutant C57 BL/KsJ mice: relation to age and hyperglycemia. Dev Brain Res1985; 20: 161–168.
9.
GarrisDRMichelME: Regional brain glucose uptake in genetically diabetic C57 BL/KsJ mice: modulation by the opiate antagonist, Nalmefene. Brain Res1988; 445: 262–267.
10.
LoubatieresA: The hypoglycemic sulfonamides: history and development of the problem from 1942 to 1945. Ann NY Acad Sci1957; 71: 4–11.
11.
LebovitzHEFeinglosMNBucholtzHK: Potentiation of insulin action: a probable mechanism for the antidiabetic action of sulfonylurea drugs. J Clin Endocrinol Metab1977; 45: 601–604.
12.
HalterJBGrafRJPorteD: Potentiation of insulin secretory response by plasma glucose levels in man: evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation. J Clin Endocrinol Metab1979; 48: 946–954.
13.
GeisenKHitzelVOkomonopoulesR: Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antibodies. Arzneimittelforschung1985; 35: 707–712.
14.
KaubischNHammerRWolheimC: Specific receptors for sulfonylureas in brain and in a beta-cell tumor of the cat. Biochem Pharmacol1982; 31: 1171–1174.
15.
YalowRSBlackHVillazonM: Comparison of plasma insulin levels following administration of tolbutamide and glucose. Diabetes1960; 9: 356–362.
16.
MadsenJ: Extrapancreatic and intrapancreatic action of antidiabetic sulfonylureas. A review. Acta Med Scand1967; 476 (suppl): 109–122.
17.
BruniJFWatkinsWBYenSSC: Beta-endorphin in the human pancreas. J Clin Endocrinol Metab1979; 49: 649–651.
18.
ReidRLYenSSC: Beta-endorphin stimulates the secretion of insulin and glucagon in humans. J Clin Endocrinol Metab1981; 52: 592–594.
19.
FeldmanMKiserRSUngerRH: Beta-endorphin and the endocrine pancreas: studies in healthy and diabetic human beings. N Engl J Med1983; 308: 349–353.
20.
KoltaMGWilliamsBB: Effect of hyperglycemia on biogenic amines, beta-endorphin and insulin of the rat brain. Horm Metabol Res1984; 16: 16–20.
21.
BelonJPOroscoMHenryJC: Variations in beta-endrophin levels in response to an oral glucose tolerance test in non-insulin diabetic subjects. Med Sci Res1988; 16: 565–566.
22.
MatsumaraMFukushimaTSaitoH: In vivo and in vitro effects of beta-endorphin on glucose metabolism in the rat. Horm Metab Res1984; 16: 27.
23.
MorleyJELevineAS: The central control of appetite. Lancet1983; i: 398–401.
24.
MorleyJELevineASGosnellBA: The kappa opioid receptor ingestive behaviors and the obese mouse (ob/ob). Physiol Behav1983: 31: 603–606.
25.
IppEDhoraJWalaJ: Effects of an enkephalin analog on endorphin function and glucose homeostasis in normal and diabetic dogs. Endocrinology1982; III: 2110–2115.
26.
ScheenAJLefebvrePJLuyckxAS: Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients. Eur J Clin Pharmacol1984; 26: 471–474.
27.
LebovitzHEFeinglosMN: Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care1978; 1: 189–198.
28.
SamolsETylerJMMialheP: Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas. Lancet1969; i: 174–176.
29.
PentikainenPJNeuvonenPJPenttilaA: Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol1983; 21: 98–107.
30.
FiissgangerRDSüssmanHHagerG: Glucagon – insulin interrelationships in the regulation of islet cell functions. In: Endocrinology (JamesVHT, ed), Vol 2. Oxford: Excerpta Medica, 1977; pp 558–567.
31.
HermansenK: Enkephalins and the secretion of pancreatic somatostatin and insulin in the dogs. Endocrinology1983; 113: 1149–1153.
32.
SamolsEWeirGCRamseurR: Modulation of pancreatic somatostatin by adrenergic and cholinergic agonism and by hyper- and hypoglycemic sulfonamides. Metabolism1978; 27 (suppl 1): 1219–1221.
33.
EfendicSEnzmannFNylenA: Sulfonylurea (glibenclamide) enhances somatostatin and inhibits glucagon release induced by arginine. Acta Physiol Scand1980; 108: 231–233.
34.
LeslieRDPykeDAStubbsWA: Sensitivity to enkephalins as a cause of non-insulin dependent diabetes. Lancet1979; i: 341.
35.
MorleyJELevineAS: The role of the endogenous opiates as regulators of appetite. Am J Clin Nutr1982; 35: 757–765.
36.
BerglandRMPageRB: Pituitary – brain vascular relations: a new paradigm. Science1979: 204: 18–24.
37.
BelonJPOroscoMJacquotC: β-endorphin secretions in response to hyperglycemia. I: in streptozotocin-diabetic rats. Acta Ther1989; 15: 1–11.
